Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jennifer J Clark

Showing results (21-30 of 24) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 24 results.
Plos Medicine|July 13, 2006
MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasiaYana Pikman, Benjamin H Lee, Thomas Mercher, et al.
Blood|August 6, 2005
The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemiaRoss L Levine, Marc Loriaux, Brian J P Huntly, et al.
Cancer Discovery|March 17, 2019
Patient-Driven Discovery, Therapeutic Targeting, and Post-Clinical Validation of a Novel <i>AKT1</i> Fusion-Driven CancerEmily K Slotkin, Daniel Diolaiti, Neerav N Shukla, et al.
Cancer Cell|April 20, 2005
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosisRoss L Levine, Martha Wadleigh, Jan Cools, et al.
Pageof 3

Showing results (21-30 of 24) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 24 results.
Plos Medicine|July 13, 2006
MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasiaYana Pikman, Benjamin H Lee, Thomas Mercher, et al.
Blood|August 6, 2005
The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemiaRoss L Levine, Marc Loriaux, Brian J P Huntly, et al.
Cancer Discovery|March 17, 2019
Patient-Driven Discovery, Therapeutic Targeting, and Post-Clinical Validation of a Novel <i>AKT1</i> Fusion-Driven CancerEmily K Slotkin, Daniel Diolaiti, Neerav N Shukla, et al.
Cancer Cell|April 20, 2005
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosisRoss L Levine, Martha Wadleigh, Jan Cools, et al.
Pageof 3